Boehringer Ingelheim has started a registration trial of its experimental therapy brigimadlin as a treatment for dedifferentiated liposarcoma ... of the MDM2 gene. At the moment, the only ...
BI 907828 binds directly to MDM2 and blocks its interaction with p53, leading to stabilization of p53, TP53 target gene induction ... advanced dedifferentiated liposarcoma, will start recruiting ...
MDM2 turnover and expression of ATRX determine the choice ... Application of molecular biology to individualize therapy for patients with liposarcoma. Am Soc Clin Oncol Educ Book. 2015:213-8 Dickson ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback